Akèy › Myelom Miltip › North Carolina
Etid klinik pou Myelom Miltip nan North Carolina
52 etid pou Myelom Miltip ap chèche patisipan nan sit nan North Carolina.
Vil nan North Carolina
Tèks ofisyèl etid la (Anglè)
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Charlotte
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07391657A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Levine Cancer Institute, Charlotte
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT05652335A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Duke University Medical Center, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07518186A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
- Duke University Medical Center, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06500884A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Atrium Health, Charlotte
- Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center, Winston-Salem
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 25, 2026 · NCT07149857A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina, Chapel Hill
- Durham VAMC, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07258511Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study
- Wake Forest University, School of Medicine Dept. of Internal Medicine, Division of Hematology Oncology, Winston-Salem
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06052826A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
- Durham VAMC, Durham
- ak 3 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05552222A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Levine Cancer Institute, Charlotte
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05201781A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- Atrium Health Levine Cancer Institute, Charlotte
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07116616A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
- University of North Carolina at Chapel Hill /ID# 277708, Chapel Hill
Ap rekriteFaz 2/3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07095452TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Lineberger Comprehensive Cancer Center, Chapel Hill
- Atrium Health's Levine Cancer Institute, Charlotte
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT02693535Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Duke University, Durham
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07648264A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Medical Center, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06297226A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
- University of North Carolina at Chapel Hill /ID# 272454, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
- Wake Forest Baptist Health /ID# 271294, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT06953960Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Novant Health Cancer Institute, Charlotte
- Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 11, 2026 · NCT07555938HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM
- Duke University Health System, Durham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06822972Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Hillsborough
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT06375044A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- GSK Investigational Site, Chapel Hill
- GSK Investigational Site, Wilson
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT05714839Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Southeastern Medical Oncology Center-Clinton, Clinton
- Southeastern Medical Oncology Center-Goldsboro, Goldsboro
- Southeastern Medical Oncology Center-Jacksonville, Jacksonville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04566328A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Atrium Health, Levine Cancer Institute, Charlotte
- Duke University Hospital, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 18, 2026 · NCT05651932AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Charlotte
- Research Site, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05850234Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
- Research Site, Chapel Hill
- Research Site, Charlotte
- Research Site, Durham
- ak 2 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT07764978DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill
Ap rekrite
Laj 60 ak plis · Tout sèks · Mizajou Aug 14, 2026 · NCT06296368A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
- Duke Cancer Center, Durham
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 12, 2026 · NCT07280013A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- UNC Hospitals Adult Oncology Clinics, Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07284758A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
- University of North Carolina at Chapel Hill /ID# 274667, Chapel Hill
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
- Atrium Health Wake Forest Baptist Medical Center /ID# 274847, Winston-Salem
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 21, 2026 · NCT06892522Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Duke Institute of Cancer/ Duke University, Durham
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT02343042Pre-malignant States to Hematologic Malignancies in Firefighters
- Levine Cancer Institute, Charlotte
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 40 a 49 · Tout sèks · Mizajou Jul 13, 2026 · NCT06870760CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
- Atrium Health Levine Cancer, Charlotte
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 30 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT06644625A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of North Carolina /ID# 251203, Chapel Hill
- Atrium Health Wake Forest Baptist Medical Center /ID# 251165, Winston-Salem
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT05650632A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- University of North Carolina at Chapel Hill, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jul 8, 2026 · NCT05137054A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
- University of North Carolina (Data Collection Only), Chapel Hill
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 6, 2026 · NCT06083922Registry of Older Patients With Cancer
- Seby B. Jones Cancer Center, Boone
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill
- East Carolina University, Greenville
- ak 4 plis
Ap rekriteEtid obsèvasyon
Laj 65 ak plis · Tout sèks · Mizajou Jun 29, 2026 · NCT01137825Integrated Cancer Repository for Cancer Research
- Cape Fear Valley Health System, Fayetteville
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
- Levine Cancer Institute, Charlotte
- Duke University, Durham
- East Carolina University, Greenville
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT05243797Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of North Carolina, Chapel Hill
Ap rekriteFaz 2
Laj 19 ak plis · Tout sèks · Mizajou Jun 4, 2026 · NCT06974786Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill
- Levine Cancer Institute, Charlotte
- Duke Comprehensive Cancer Center, Durham
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 2, 2026 · NCT05145400Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- University of North Carolina Hospitals at Hillsborough, Chapel Hill
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou May 19, 2026 · NCT06433947Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.